YOLFTbeta
37

Xcell Therapeutics Inc.

373110 · KQ · Healthcare / Biotechnology

868.00KRW+30.00 (+3.58%)

Price History

Full chart

Market Stats

Previous Close838.00
Open845.00
Day Range845.00 – 909.00
52-Week Range951.00 – 2,755.00
Volume30.13K
Market Cap17.17B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta1.29
50-Day Avg1,134.74
200-Day Avg1,396.42

About

Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. The company also offers XPorT, a platform that aims to develop optimal media from the perspective of the user using a variety of cells. In addition, it develops media for cell culture in various areas of the bioindustry such as cell therapy, gene therapy, exosomes, organoids and bioreactors. Xcell Therapeutics Inc. was founded in 2015 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • Employees67
  • HeadquartersDongwon Building, Seoul, South Korea, Korea
  • Websitehttps://xcell.co.kr/kor/

Financials

Income Statement

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.97B1.02B1.12B1.93B1.95B
Growth (%)--48.12%+10.18%+72.11%+0.76%
Cost of Revenue2.27B2.76B2.98B3.33B3.90B
Gross Profit-305.34M-1.74B-1.86B-1.39B-1.95B
Gross Margin-15.53%-170.90%-165.19%-71.94%-100.29%
Operating Expense5.40B6.55B7.00B7.94B8.90B
Operating Income-5.71B-8.30B-8.86B-9.33B-10.85B
Operating Margin-290.14%-813.45%-788.32%-482.18%-556.79%
EBITDA--6.83B-7.68B-7.89B-9.22B
EBITDA Margin--669.27%-683.27%-407.70%-473.04%
Net Income-9.04B-8.34B-9.28B-9.54B-10.93B
Net Income Margin-459.67%-817.85%-825.74%-493.35%-560.65%
R&D1.83B2.60B2.75B2.73B2.58B
R&D as % of Total Revenue93.19%254.53%244.93%141.03%132.15%
Interest Expense179.78M2.89M3.12M4.40M3.43M
Interest Expense % of Total Revenue9.14%0.28%0.28%0.23%0.18%

Balance Sheet

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets23.70B15.51B10.47B16.89B15.72B
Total Liabilities7.48B7.03B8.08B7.77B8.58B
Total Equity16.22B8.48B2.38B9.12B7.14B
Cash14.63B482.00K547.00K7.76B2.09B
Net Debt--3.98B-2.54B

Cash Flow

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-4.61B-7.30B-6.78B-7.00B-9.50B
Investing Cash Flow--1.47B-178.55M-1.27B-
Financing Cash Flow--438.88M2.76B14.79B-
Capital Expenditure1.40B1.32B233.65M820.04M1.18B
Free Cash Flow-6.00B-8.62B-7.02B-7.82B-10.69B
FCF to OCF130.31%118.15%103.44%111.72%112.45%

Earnings

Report DateSep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate--------
EPS Actual-216.74-197.35-205.31-217.53-185.98-247.00-169.38-159.68
Surprise--------
Timing--------

Key Statistics & Ratios

Market Cap17.17B
Enterprise Value18.43B
Trailing P/E0.00
Forward P/E0.00
Price / Sales3.94
Price / Book3.99
Revenue (TTM)4.36B
Gross Profit (TTM)-1.89B
EBITDA-9.66B
Profit Margin-260.88%
Operating Margin-142.19%
Return on Equity-271.41%
Return on Assets-57.12%
Shares Outstanding17.29M
Shares Float14.08M
Beta1.29
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%